Q-omics provides the consensus-scored CDC42BPA profile across patient tissues and cancer cell-line models. CDC42BPA expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDC42BPA is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CDC42BPA protein abundance shows 21,360 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where CDC42BPA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC42BPA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC42BPA survival associations across molecular data types. CDC42BPA RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC42BPA RNA expression–survival associations across cancer types. High CDC42BPA expression shows unfavorable associations in STAD, UVM, ACC, BLCA and MESO, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDC42BPA RNA expression.
This table summarizes CDC42BPA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CDC42BPA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC42BPA shows lower tumor expression in COAD, KICH and BLCA and higher tumor expression in HNSC, LIHC and LUAD. The HNSC box plot shows higher CDC42BPA RNA expression in tumor versus normal tissue (log2 FC = +1.042, t-test p < 0.001).
This table shows molecular features associated with CDC42BPA in patient tissues and cancer cell lines. In patient samples, CDC42BPA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC42BPA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
